Generating automated kidney transplant biopsy reports combining molecular measurements with ensembles of machine learning classifiers
- PMID: 30868758
- DOI: 10.1111/ajt.15351
Generating automated kidney transplant biopsy reports combining molecular measurements with ensembles of machine learning classifiers
Erratum in
-
Erratum.Am J Transplant. 2020 Feb;20(2):620-621. doi: 10.1111/ajt.15770. Epub 2020 Jan 18. Am J Transplant. 2020. PMID: 31983081 No abstract available.
Abstract
We previously reported a system for assessing rejection in kidney transplant biopsies using microarray-based gene expression data, the Molecular Microscope® Diagnostic System (MMDx). The present study was designed to optimize the accuracy and stability of MMDx diagnoses by replacing single machine learning classifiers with ensembles of diverse classifier methods. We also examined the use of automated report sign-outs and the agreement between multiple human interpreters of the molecular results. Ensembles generated diagnoses that were both more accurate than the best individual classifiers, and nearly as stable as the best, consistent with expectations from the machine learning literature. Human experts had ≈93% agreement (balanced accuracy) signing out the reports, and random forest-based automated sign-outs showed similar levels of agreement with the human experts (92% and 94% for predicting the expert MMDx sign-outs for T cell-mediated (TCMR) and antibody-mediated rejection (ABMR), respectively). In most cases disagreements, whether between experts or between experts and automated sign-outs, were in biopsies near diagnostic thresholds. Considerable disagreement with histology persisted. The balanced accuracies of MMDx sign-outs for histology diagnoses of TCMR and ABMR were 73% and 78%, respectively. Disagreement with histology is largely due to the known noise in histology assessments (ClinicalTrials.gov NCT01299168).
Keywords: basic (laboratory) research/science; biopsy; kidney failure/injury; kidney transplantation/nephrology; microarray/gene array; molecular biology; rejection: T cell mediated (TCMR); rejection: antibody-mediated (ABMR).
© 2019 The American Society of Transplantation and the American Society of Transplant Surgeons.
References
REFERENCES
-
- Jameson JL, Longo DL. Precision medicine - personalized, problematic, and promising. N Engl J Med. 2015;372(23):2229-2234.
-
- Eskandary F, Regel H, Baumann L, et al. A randomized, placebo-controlled trial of bortezomib in late antibody-mediated kidney transplant rejection: the BORTEJECT study. J Am Soc Nephrol. 2017;29(2):591-605.
-
- Eskandary F, Jilma B, Mulbacher J, et al. Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection - results from a first-in-patient phase 1 trial. Am J Transplant. 2018;18(4):916-926.
-
- Loupy A, Haas M, Solez K, et al. The Banff 2015 Kidney Meeting Report: current challenges in rejection classification and prospects for adopting molecular pathology. Am J Transplant. 2017;17(1):28-41.
-
- Furness PN, Taub N, Assmann KJ, et al. International variation in histologic grading is large, and persistent feedback does not improve reproducibility. Am J Surg Pathol. 2003;27(6):805-810.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
